Safety, PD & Efficacy of MT-3724 for the Treatment of Patients With Relapsed or Refractory DLBCL
Status:
Terminated
Trial end date:
2021-03-22
Target enrollment:
Participant gender:
Summary
The purpose of this study is to evaluate the safety and tolerability of MT-3724 in subjects
with relapsed or refractory B-Cell NHL or relapsed and refractory CLL (Part 1 only) and
relapsed and refractory DLBCL (Part 2 and Part 3). Part 3 evaluates the efficacy of MT-3724.